Wave Life Sciences Ltd. 8-K

What Happened

• Wave Life Sciences Ltd. (WVE) filed an 8-K on June 26, 2026 reporting that shareholders approved a scheme of arrangement to complete the company's redomiciliation.
• A special meeting of Scheme Shareholders was held June 22, 2026 at 1:00 p.m. ET at the direction of the Singapore High Court; the Scheme was approved and the company will apply for final court approval. Wave-Singapore expects the redomiciliation to take effect in mid‑2026, subject to the Singapore High Court’s approval.

Key Details

• Vote results: 155,190,836 shares FOR, 78,429 shares AGAINST, total 155,269,265 shares voted (≈99.95% FOR).
• Number of Scheme Shareholders voting: 87 FOR, 0 AGAINST (total 87).
• vote related to a Scheme of Arrangement under Singapore law; CEDE & Co. holdings were excluded from Scheme Shareholders.
• Reference: definitive proxy statement filed May 7, 2026; company will file an application to the Singapore High Court for final approval.

Why It Matters

• The shareholder approval is the key shareholder step toward changing the company’s legal domicile (redomiciliation); final effectiveness depends on Singapore High Court approval.
• For investors, approval reduces a major procedural hurdle and makes the mid‑2026 redomiciliation more likely, which could affect corporate governance, regulatory oversight, and future filings once the change is effective. The filing does not announce any immediate change to trading or share treatment pending court action.